Izotropic Announces Debt Settlement

• Event: Izotropic Corporation announced a debt settlement agreement on April 21, 2026.
• Settlement Details: The company settled $100,000 of the principal balance from an existing $2,000,000 promissory note dated April 1, 2022.
• Consideration: Settlement executed via issuance of 500,000 units at a deemed price of $0.20 per unit.
• Unit Composition: Each unit consists of one common share and one share purchase warrant.
• Warrant Terms: Exercise price of $0.20 per warrant share; expiry three years from issuance date.
• Regulatory Status: Completion is subject to approval by the Canadian Securities Exchange (CSE).
• Hold Period: All securities are subject to a statutory hold period of four months and one day.

• Dilution Impact: The issuance of 500,000 units at $0.20 represents significant dilution relative to the company's recent financing activity (e.g., Feb 4, 2026 raised $300k via 1.2M units).
• Price Discount: The settlement price of $0.20 is below the recent trading range ($0.22-$0.25 as of late April 2026), indicating a discount issuance that negatively impacts existing shareholder value.
• Debt Reduction vs. Cash Flow: While reducing principal debt by $100,000, this action confirms continued reliance on equity financing to service liabilities rather than operational cash flow. The remaining note balance is approximately $1.9 million plus accrued interest.
• Context of History: This follows a pattern established in December 2025 and February 2026 where debt interest ($60,000) was settled via equity issuance. It suggests liquidity constraints persist despite the recent $300,000 private placement.
• Market Expectation: Given the prior announcements regarding financing needs and debt settlement in early 2026, this is largely expected behavior for a company at this development stage, limiting its "game changer" status but maintaining negative sentiment due to terms.

• Company: Izotropic Corporation focuses on medical imaging technology.
• Flagship Product: IzoView Breast CT Imaging System, designed for breast cancer detection.
• Development Status: Seeking regulatory approval and commercial deployment; currently pursuing international expansion via a subsidiary structure in Africa.
• Strategic Focus: Expansion into African and Gulf Cooperation Council (GCC) markets through "Izotropic Africa," targeting regions with high breast cancer mortality rates due to delayed diagnosis.